Short Interest in Evaxion Biotech A/S (NASDAQ:EVAX) Expands By 6.3%

Evaxion Biotech A/S (NASDAQ:EVAX) saw a large growth in short interest in June. As of June 15th, there was short interest totalling 45,400 shares, a growth of 6.3% from the May 31st total of 42,700 shares. Based on an average daily trading volume, of 45,900 shares, the days-to-cover ratio is currently 1.0 days.

Wall Street Analyst Weigh In

EVAX has been the subject of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of Evaxion Biotech A/S in a report on Tuesday, June 4th. LADENBURG THALM/SH SH upgraded Evaxion Biotech A/S from a “neutral” rating to a “buy” rating and set a $8.00 price target for the company in a research note on Tuesday, April 2nd.

Evaxion Biotech A/S Stock Up 9.7 %

Evaxion Biotech A/S stock opened at $3.18 on Thursday. The business has a 50-day simple moving average of $3.49 and a two-hundred day simple moving average of $4.40. The company has a market cap of $17.20 million, a P/E ratio of -0.73 and a beta of -0.28. Evaxion Biotech A/S has a 52-week low of $2.26 and a 52-week high of $13.82.

Evaxion Biotech A/S (NASDAQ:EVAX) last released its quarterly earnings results on Tuesday, May 28th. The company reported $0.03 earnings per share (EPS) for the quarter. The firm had revenue of $0.05 million for the quarter. Research analysts anticipate that Evaxion Biotech A/S will post -0.1 EPS for the current fiscal year.

Institutional Investors Weigh In On Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. LM Advisors LLC acquired a new stake in shares of Evaxion Biotech A/S (NASDAQ:EVAX) during the fourth quarter, according to its most recent disclosure with the SEC. The fund acquired 337,336 shares of the company’s stock, valued at approximately $231,000. LM Advisors LLC owned approximately 8.90% of Evaxion Biotech A/S as of its most recent SEC filing. 11.04% of the stock is currently owned by institutional investors.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.